TSO3 announces the Results of the Votes from its Annual and Special Meeting of the Shareholders

QUÉBEC CITY, May 5, 2016 /CNW Telbec/ - TSO₃ Inc. (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings, today announced that the nominees listed in the management proxy circular dated March 22, 2016, were elected as directors of TSO₃ Inc. In addition, all other proposals submitted by management were approved.

­Election of Directors

The shareholders were asked to provide their decision via a vote by proxy as part of TSO₃ Annual General Meeting of Shareholders, held on May 4, 2016 in Québec. The detailed results of the vote are set out below.

Name	Votes for	% for	Votes against	% against	Withheld/ Abstain	% withheld
Germain Carrière	35,429,726	95.17	0	0	1,799,908	4.83
Pierre Désy	36,463,106	97.94	0	0	766,528	2.06
Jean Lamarre	35,388,316	95.05	0	0	1,841,318	4.95
Claude Michaud	35,790,756	96.14	0	0	1,438,878	3.86
Jean-Pierre Robert	36,840,666	98.96	0	0	388,968	1.04
Richard M. Rumble	37,189,728	99.89	0	0	39,906	0.11
Steve West	37,182,448	99.87	0	0	47,186	0.13
Other Proposals
Appointment of Independent Auditors	41,759,965	99.95	0	0	21,035	0.05
Adoption of the 2016 Stock Incentive Plan	24,293,413	65.25	12,936,221	34.75	0	0.00
Increase the number of the Stock Option Plan	29,928,651	80.39	7,300,983	19.61	0	0.00
Amendments to articles	36,266,128	97.41	963,506	2.59	0	0.00

­

Final voting results on all matters voted at the Annual Meeting of Shareholders held on May 4, 2016, will be filed on SEDAR (www.sedar.com) under the name TSO₃.

About TSO₃

Founded in 1998, TSO₃ is committed to improving the standard of healthcare sterile reprocessing by providing breakthrough sterilization systems, related consumable supplies and accessories for heat-sensitive medical devices. TSO₃ designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low-temperature sterilization processes currently used in hospitals. It also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.

For more information about TSO₃, visit the company's web site at www.tso3.com.

The statements in this release and oral statements made by representatives of TSO₃ relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of TSO₃'s sales, business or operations) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO₃ to obtain financing on favourable terms and other risks and uncertainties.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful.

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.

SOURCE TSO3 Inc.

Company Contacts: TSO3 Inc., R.M. (Ric) Rumble, President and CEO, Tel: [phone], Email: [email protected]; TSO3 Inc., Glen Kayll, CFO, Tel: [phone], Email: [email protected]; Investor Relations: Liolios Group, Inc., Ron Both, Tel: [phone], [email protected]; Renmark Financial Communications Inc., Barry Mire, Tel: [phone] or 514 939-3989, [email protected]